West Deptford, NJ – September 17, 2013 – Established in 2007, Enclara is experiencing its fourth consecutive year in adding over 5,000 patients and 40 new customers to its footprint of service. Andy Horowitz, President and Founder states, “Even though we are excited about our continued success, our sights are still focused on our core value of the ‘customer experience’ and ensuring that our first customer continues to feel our focus for timely, quality patient service, while our new customers feel the attention to detail and personal, executive touch.”
Enclara provides both a mail order comprehensive pharmacy model, as well as a “Choice” option for local drug dispenser that allows its customers to choose the level of clinical support needed while maximizing an aggressive PBM cost schedule. With a continued focus on reimbursement challenges, being solid in both service models allows the customers to match the options to their territory of service and needs of their patients.
Enclara practices an active partnership model by reviewing utilization patterns and suggesting appropriate as well as cost effective measures for care. Many of their customers have seen a dramatic non-formulary cost decrease over the other leading mail order provider, based on an interactive pharmacy consultation model vs. passive formulary dispense. Their technology platform allows for the control of utilization through hard-stop authorization processes and putting the control back in their hospice partners’ hands.
“After 7 years of business, Enclara has taken its rightful place as a leading provider model in the industry of hospice pharmacy. We look forward to our continued growth through the rest of 2013 and an even healthier 2014.”